[Molecular remission of chronic myeloid leukaemia in a patient with hepatitis and a second kidney transplant].

Abstract

Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by clonal expansion of cells in the myeloid line, expressing the BCR-ABL fusion protein responsible for the oncogenic effect of CML. The current frontline therapy in CML is the BCR-ABL tyrosine kinase inhibitor, Imatinib. Although this drug has been shown to improve survival in CML patients, its role in the context of a transplant setting has not been widely described in the literature. We report on the long term molecular remission of CML in a 55 year old man with a second renal transplant who is hepatitis C virus positive, and has associated cardiovascular and immunological risk factors.

• Authors: M Castillo-Rama, C Grande, P Martínez-Sanchez, E Olavarria, D Marín, E Paz-Artal, A Andrés, J M Morales
• Journal: Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia (Nefrologia) Vol. 29 Issue 6 Pg. 604-7 ( 2009) ISSN: 0211-6995 [Print] Spain
• Vernacular Title: Remisión molecular de una leucemia mieloide crónica en un paciente con segundo trasplante renal y hepatitis.
• PMID: 19936007 (Publication Type: Case Reports, English Abstract, Journal Article)

Topics

• Hepatitis C (complications)
• Humans
• Kidney Transplantation
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive (complications, surgery)
• Male
• Middle Aged
• Remission Induction
• Reoperation